A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis

BACKGROUND: To evaluate the immunomodulating and clinical effects of nilotinib, a tyrosine kinase inhibitor, in a proof-of-concept study in spondyloarthritis (SpA) assessing the mast cell as potential novel therapeutic target in this disease. METHODS: Twenty eight patients with active peripheral (pS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Transl Med
Main Authors: Paramarta, Jacqueline E., Turina, Maureen C., Noordenbos, Troy, Heijda, Tanja F., Blijdorp, Iris C., Yeremenko, Nataliya, Baeten, Dominique
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081668/
https://ncbi.nlm.nih.gov/pubmed/27784336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1050-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados